Two case series address hyperglycemia-related problems
One series describes patients who received enfortumab vedotin and then had hyperglycemia or diabetic ketoacidosis, while the other reports on some patients belatedly diagnosed with latent autoimmune diabetes of adults.
Two recent articles from Annals of Internal Medicine: Clinical Cases dealt with glycemic control issues.
One report, published May 6, described three instances of hyperglycemia or diabetic ketoacidosis in patients who received enfortumab vedotin (a biologic drug typically used for metastatic urothelial carcinoma) at one center. The first case involved insulin-resistant diabetic ketoacidosis requiring large doses of insulin and led to fatal hemodynamic shock. In the second case, the patient presented with hyperglycemia, symmetrical muscle weakness, and diffuse cutaneous eruption. The third case consisted of mild diabetic ketoacidosis, rash, jaundice, and confusion.
The other case series, published June 3, also included three patients, all of whom were initially diagnosed with type 2 diabetes and treated with oral antidiabetic medications. After referral to an endocrinology clinic due to poor glycemic control, the patients were diagnosed with latent autoimmune diabetes of adults due to the isolated presence of zinc-transporter-8 antibody.